Editas Medicine said Tuesday it will license out or partner its lead sickle cell treatment, the latest shift for a tarantella company that has repeatedly
SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according
Newly published data show that seven out of 67 children who received Bluebird Bio’s gene therapy for a devastating neurological disorder in clinical trials have
Two of the first efforts to treat Duchenne muscular dystrophy with CRISPR gene editing are getting off the ground in China, even as projects in
Prime Medicine, founded with gene editing tech from the lab of star Harvard biochemist David Liu and backed by blue chip investors, made little secret
The Food and Drug Administration on Friday approved the first treatment for Niemann-Pick disease, type C, the culmination of years of advocacy and stutter-start drug
A long-running race to develop a gene therapy for the most common cause of age-related blindness is heating up. On Wednesday, 4D Molecular Therapeutics announced
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and targeted drugs have joined or replaced older, blunter tools like
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal, fell short in a randomized trial reported Tuesday afternoon. Athira
NEW YORK — Sixteen floors above Central Park, Kris White keeps his gentler pathogens behind an unlocked stainless steel freezer door, in brightly colored boxes